58k+ listingsShips to NLResponse within one hour+31 73 711 4717info@questpair.com

Applied Biosystems 7900

This model was found in 2,243 unique locations in 54 countries, where it was mentioned from 2003 until recently.

  • prism sequence detection
  • sequence detector
  • instrument
  • machine
locations where this model was found
2,243
countries where the model is used
54
related research fields
141
first year this model was mentioned
2003

About the Applied Biosystems 7900

Questpair Analytics found the Applied Biosystems 7900 at 2,243 research organisations and laboratories in 54 countries, in publications from 2003 until recently. It is used most in Cancer Research, Molecular Biology and Genetics.

Usage over time

Mentions per year, 2003–2020

Mentions peaked in 2013.

Research fields

141 related research fields

The Applied Biosystems 7900 is used by scientists in research fields such as Cancer Research, Molecular Biology, Genetics, Oncology and General Medicine.

  • Cancer Research
  • Molecular Biology
  • Genetics
  • Oncology
  • General Medicine
  • Immunology
  • Cell Biology
  • Immunology and Allergy
  • General Biochemistry, Genetics and Molecular Biology
  • Molecular Medicine
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Pharmacology
  • Genetics (clinical)
  • Physiology
  • Internal Medicine
  • Biotechnology
  • General Neuroscience
  • General Chemistry
  • Pathology and Forensic Medicine
  • General Physics and Astronomy
  • Developmental Biology
  • Microbiology
  • Toxicology
  • Infectious Diseases
  • Neurology
  • Organic Chemistry
  • Clinical Biochemistry
  • Physical and Theoretical Chemistry
  • + 111 more

Organisations using this equipment

The model was found at 2,243 locations in 54 countries.

2,243 locations in 54 countries
OrganisationInstrumentCityCountry
University of Bergen
Applied Biosystems 7900HTBergenNorway
University of Cagliari
Applied Biosystems 7900HTCagliariItaly
Soonchunhyang University
Applied Biosystems 7900HTBucheon-siSouth Korea
"Queens University Belfast"
Applied Biosystems 7900HTBelfastUnited Kingdom
University of Waterloo
Applied Biosystems 7900HTWaterlooCanada
University of Toronto
Applied Biosystems 7900HTTorontoCanada
7–12 of 2,243

Research that uses the Applied Biosystems 7900

Only abstracts that are published under Creative Commons Attribution 4.0 are shown on this page.

Cardioprotective Natural Compound Pinocembrin Attenuates Acute Ischemic Myocardial Injury via Enhancing Glycolysis

Purpose. Emerging evidence has shown that pinocembrin protects the myocardium from ischemic injury in animals. However, it is unknown whether it has cardioprotection when given at the onset of reperfusion. Also, mechanisms mediating the cardioprotective actions of pinocembrin were largely unknown. Thus, this study is aimed at investigating the effects of pinocembrin postconditioning on ischemia-reperfusion (I/R) injury and the underlying mechanisms. Methods. The in vivo mouse model of myocardial I/R injury, ex vivo isolated rat heart with global I/R, and in vitro hypoxia/reoxygenation (H/R) injury model for primary cardiomyocytes were used. Results. We found that pinocembrin postconditioning significantly reduced the infarct size and improved cardiac contractile function after acute myocardial I/R. Mechanically, in primary cardiomyocytes, we found that pinocembrin may confer protection in part via direct stimulation of cardiac glycolysis via promoting the expression of the glycolytic enzyme, PFKFB3. Besides, PFKFB3 inhibition abolished pinocembrin-induced glycolysis and protection in cardiomyocytes. More importantly, PFKFB3 knockdown via cardiotropic adeno-associated virus (AAV) abrogated cardioprotective effects of pinocembrin. Moreover, we demonstrated that HIF1α is a key transcription factor driving pinocembrin-induced PFKFB3 expression in cardiomyocytes. Conclusions. In conclusion, these results established that the acute cardioprotective benefits of pinocembrin are mediated in part via enhancing PFKFB3-mediated glycolysis via HIF1α, which may provide a new therapeutic target to impede the progression of myocardial I/R injury.

Yanjun Zheng, Guoqing Wan, Bo Yang, Xuefeng Gu, Jingrong Lin. Oxidative Medicine and Cellular Longevity, 2020, 1-13, 2020.

Read the publication
An In Vitro Verification of the Effects of Paeoniflorin on Lipopolysaccharide-Exposed Microglia

Background. The neuroprotective effects of Paeoniflorin (PF) are well known. Most of the evidence was verified in vivo. We attempted to perform an in vitro verification of the effects of PF in microglia. Methods. A lipopolysaccharide- (LPS-) exposed microglia model was employed. An enzyme-linked immunosorbent assay was used to measure the levels of cytokines in the culture supernatants. A real-time polymerase chain reaction was performed to measure the mRNA expression of cytokines and M1- and M2-like genes. A western blot analysis was used to examine the expression of proteins associated with the nuclear factor-kappa B (NF-κB) signaling pathway. Results. We found that the administration of PF reversed the inflammatory response induced by LPS. It downregulated proinflammatory cytokines and upregulated anti-inflammatory cytokines. This, in turn, alleviated the oxidative injuries, downregulated the expression of M1-like genes, and upregulated the expression of M2-like genes. PF can also reverse the changes in proteins associated with the NF-κB signaling pathway induced by LPS. Conclusions. We provided evidence obtained in vitro concerning the neuroprotective effects of PF via suppressing activation of microglia, which might be associated with the NF-κB signaling pathway. These findings contribute to obtaining a deeper understanding of PF, a potential new treatment for brain injuries.

Qiliang Chen, Yaojun Liu, Yuanyuan Zhang, Xinyu Jiang, Yuqin Zhang, Tetsuya Asakawa. Evidence-Based Complementary and Alternative Medicine, 2020, 1-10, 2020.

Read the publication
FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway

Objective. To study the expression, biological function, and mechanism of FKBP4 in non-small-cell lung cancer (NSCLC). Methods. First of all, the expression of FKBP4 in NSCLC tissues and cell lines was detected by qRT-PCR; then, the effects of FKBP4 on proliferation, apoptosis, migration, and invasion of NSCLC were studied by CCK-8 assays, flow cytometry assays, wound-healing assays, and Transwell assays. After that, tumor xenografts were used to explore the effect of FKBP4 on NSCLC tumor growth in vivo, and the phosphorylation of Akt and mTOR was measured by western blot. Results. FKBP4 was highly expressed in NSCLC tissues and cells, and its expression was closely related to NSCLC tumor size, lymph node metastasis, and patient prognosis. In vitro, FKBP4 can promote NSCLC cell proliferation, migration, and invasion and inhibit NSCLC cell apoptosis. In vivo, FKBP4 can promote NSCLC tumor growth. Furthermore, FKBP4 can promote Akt and mTOR phosphorylation and activate the Akt/mTOR signaling pathway and an mTOR inhibitor can neutralize the functions of FKBP4 in NSCLC cells. Conclusion. FKBP4 serves as an oncogene to promote malignant processes in NSCLC, and it has the potential to be used as a biological marker and therapeutic target for NSCLC.

Wen Meng, Jingfei Meng, Hong Jiang, Xing Feng, Dongshan Wei, Qingsong Ding. Analytical Cellular Pathology, 2020, 1-11, 2020.

Read the publication
Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon Cancer

Interleukin-18 (IL-18) belongs to the IL-1 family and is an essential proinflammatory and immune regulatory cytokine. The present study was designed to investigate the expression and function of IL-18 in colon cancer. In clinical analyses, mRNA and protein expressions of IL-18 were decreased in tissues of colon cancer patients. This decreased expression of IL-18 was significantly correlated with the tumor size () and American Joint Committee on Cancer (AJCC) stage (). Patients with IL-18-positive tumors had a better survival rate than patients with IL-18-negative tumors. Moreover, upregulation of IL-18 inhibited colon cancer cell proliferation. Our data suggest that the decreased expression of IL-18 in colon cancer was associated with prognosis and tumor proliferation. IL-18 may be considered a novel tumor suppressor and a potential therapeutic target for colon cancer patients.

Xiaodong Feng, Zhijun Zhang, Peng Sun, Guanghui Song, Lu Wang, Zhenqing Sun, Ning Yuan, Qing Wang, Limin Lun. Disease Markers, 2020, 1-9, 2020.

Read the publication
BASP1 Suppresses Cell Growth and Metastasis through Inhibiting Wnt/β-Catenin Pathway in Gastric Cancer

Objective. Our research is designed to explore the function of brain acid soluble protein 1 (BASP1) in the progression of gastric cancer (GC) and its underlying molecular mechanisms. Methods. In this study, the expression of BASP1 was detected by quantitative real-time polymerase chain reaction (qRT-PCR) in both GC tissue and GC cells. The cell cloning, proliferation, apoptosis, migration, and invasion potential of AGS and HGC-27 cells were, respectively, determined using colony formation assay, 5-ethynyl-20-deoxyuridine (EDU) assay, flow cytometry, and Transwell assay. The protein expressions of Bax, caspase-3, Bcl-2, matrix metalloproteinases 2 (MMP-2), MMP-9, Wilms tumor 1 (WT1), Wnt, and β-catenin in AGS and HGC-27 cells were measured by western blot. In addition, the mRNA expressions of WT1, Wnt, and β-catenin in AGS and HGC-27 cells were detected by qRT-PCR. Results. BASP1 expression was significantly downregulated in both GC tissue and GC cells. BASP1 overexpression markedly repressed proliferation, migration, and invasion and facilitated apoptosis in AGS and HGC-27 cells. In addition, BASP1 overexpression notably promoted the protein expression of Bax and caspase-3 in AGS and HGC-27 cells and inhibited the expression of Bcl-2, MMP-2, and MMP-9. Moreover, BASP1 overexpression significantly inhibited the mRNA and protein expression of WT1, Wnt, and β-catenin in AGS and HGC-27 cells. Conclusion. BASP1 could significantly suppress cell proliferation, migration, and invasion and promote apoptosis through inhibiting the activation of the Wnt/β-catenin pathway in GC.

Li Li, Qinghua Meng, Guoying Li, Limei Zhao. BioMed Research International, 2020, 1-9, 2020.

Read the publication
Monocyte Chemotactic Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities

Monocyte chemotactic protein 1-induced protein 1 (MCPIP-1) is highly expressed in activated immune cells and plays an important role in negatively regulating immune responses. However, its role in regulating neutrophil functions in the pathogenesis of inflammatory bowel disease (IBD) is still unclear. Here, we found that MCPIP-1 was markedly increased at both the transcriptional and translational levels in inflamed mucosa of IBD patients compared with healthy controls, which was mainly expressed in neutrophils. Interestingly, MG-132, a proteasome inhibitor reducing the degradation of MCPIP-1, further facilitated neutrophils to express MCPIP-1 in vitro. Importantly, MCPIP-1 markedly downregulated the production of ROS, MPO, and proinflammatory cytokines (e.g., interleukin-1β, interleukin-6, tumor necrosis factor-α, interleukin-8, and interferon-γ) and suppressed the migration of IBD neutrophils. Consistently, the same functional changes were observed in neutrophils from mice with myeloid-targeted overexpression of MCPIP-1 as MG-132 did. Altogether, these findings suggest that MCPIP-1 plays a negative role in regulating neutrophil activities through suppressing the production of ROS, MPO, and proinflammatory cytokines and inhibiting the migration. MG-132 may partially modulate the function of neutrophils via the induction of MCPIP-1. Therefore, targeting MCPIP-1 or exogenous supplementation of MG-132 may provide a therapeutic approach in the treatment of IBD.

Jian Lin, Gengfeng Li, Chunjin Xu, Huiying Lu, Cui Zhang, Zhi Pang, Zhanju Liu. Mediators of Inflammation, 2020, 1-15, 2020.

Read the publication
Gualou Guizhi Granule Protects against OGD/R-Induced Injury by Inhibiting Cell Pyroptosis via the PI3K/Akt Signaling Pathway

Pyroptosis is a proinflammatory form of regulated cell death that plays an important role in ischemic stroke. Gualou Guizhi granule (GLGZG) is a classic prescription that has been shown to exert neuroprotective effects against cerebral ischemia reperfusion injury. In the present study, we examined the involvement of pyroptosis and its associated mechanism in protecting nerve function. Methods. Primary neurons were exposed to oxygen-glucose deprivation and reperfusion (OGD/R) conditions in the presence or absence of GLGZG. Cellular viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay. The number of apoptoic cells was detected by NeuN and NSE protein expression. The expression levels of the pyroptosis markers, namely, NOD-like receptor family pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1, interleukin-18 (IL-18), and IL-1β were determined by quantitative real-time PCR analysis, western blot, and ELISA analyses as appropriate. Moreover, the expression levels of the PI3K/Akt pathway key proteins were determined by quantitative real-time PCR analysis and western blot assays. To determine the PI3K/Akt pathway involvement in GLGZG-mediated neuroprotection, the PI3K inhibitor LY294002 (LY, 10 μM) was added. The expression levels of NeuN, Akt, and p-Akt were evaluated. Results. It was found that GLGZG could inhibit OGD/R-induced cell apoptosis, increase neuronal cell viability, decrease the production of IL-18 and IL-1β, and downregulate the expression levels of pyroptosis markers (NLRP3, ASC, and caspase-1). Furthermore, GLGZG could modulate the PI3K/Akt signaling pathway. Pharmacological inhibition of the PI3K pathway not only abrogated the effects of GLGZG on Akt but also neutralized its prosurvival and antipyroptotic actions. Conclusions. The findings indicated that GLGZG pretreatment effectively reduced OGD/R-induced injury by inhibiting cell pyroptosis and activating the PI3K/Akt pathway. These data provide important evidence for the therapeutic applications of this regimen in ischemic stroke.

Yuqin Zhang, Hongyun Wang, Huang Li, Lihong Nan, Wei Xu, Yu Lin, Kedan Chu. Evidence-Based Complementary and Alternative Medicine, 2021, 1-14, 2021.

Read the publication

About Questpair Analytics

Questpair Analytics inventorises the usage of scientific equipment such as the Applied Biosystems 7900 in research organisations and laboratories around the world. Our goal is to make it easier for professionals in research and industry to discover the availability and use cases for specific types of laboratory equipment.

We also identify locations where different brands and models are used, which we believe can help to facilitate a more efficient and circular usage of existing instruments. For example, researchers and makers can use our services to find the necessary equipment that is required to complete a specific research purpose or to analyze or create advanced materials.

Explore Questpair Analytics

Disclaimer: The data on this site is intended for educational purposes only. QuestPair assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided and presented on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness.

We find the unfindable